Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Mouse Flt-3/Flk-2 Antibody, R&D Systems™

Goat Polyclonal Antibody
Supplier: R&D Systems AF768SP
This item is not returnable.
View return policy
Description
Flt-3/Flk-2/CD135 Polyclonal specifically detects Flt-3/Flk-2/CD135 in Mouse samples. It is validated for Western Blot, Flow Cytometry, CyTOF-ready.Specifications
Flt-3/Flk-2/CD135 | |
Polyclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD135, CD135 antigen, EC 2.7.10, fetal liver kinase 2, FL cytokine receptor, Flk-2, FLK2, Flt3, FLT-3, FLT3 receptor tyrosine kinase, Fms-like tyrosine kinase 3, fms-related tyrosine kinase 3, growth factor receptor tyrosine kinase type III, Stem cell tyrosine kinase 1, STK-1, STK1EC 2.7.10.1, Tyrosine-protein kinase receptor FLT3 | |
Goat | |
Affinity Purified | |
RUO | |
2322 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Western Blot, Flow Cytometry, CyTOF | |
LYOPH | |
Western Blot 0.1 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, CyTOF-ready | |
Q00342 | |
FLT3 | |
Mouse myeloma cell line NS0-derived recombinant mouse Flt-3/Flk-2 Asn28-Ser544 Accession # Q00342 | |
25 μg | |
Primary | |
Detects mouse Flt-3/Flk-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human Flt-3 is observed. | |
Mouse | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction